NCI Pediatric In Vivo Testing Program Coordinating Center (U24 Clinical Trial Not Allowed)

Application or LOI Due Date
LOI due 10/9/20; application due 11/9/20
Brief Description

This Funding Opportunity Announcement (FOA) is for a Coordinating Center for the NCI Pediatric in Vivo Testing Program (henceforth termed the Ped-In Vivo-TP). The main goal for the Ped-In Vivo-TP is to use genomically-characterized pediatric cancer models to develop a rigorous preclinical testing system to generate reliable data that can be used to inform new agent prioritization decisions for childhood cancers.

The Ped-In Vivo-TP has two parts: a) research teams for in vivo testing to determine the activity of pediatric anticancer drug candidates, supported under RFA-CA-20-034; and b) a Coordinating Center (RFA-CA-20-041, this FOA).

The Ped-In Vivo-TP is envisioned as a way for NCI to support the Foundation for the National Institutes of Health (FNIH)-organized Public-Private Partnership (PPP) for pediatric preclinical testing. The PPP is being developed to accelerate the pace and to broaden the scope of pediatric preclinical testing of agents being developed for adult cancer indications. Pharmaceutical companies and representatives of regulatory agencies will also participate in the PPP.

This FOA invites applications for the Ped-In Vivo-TP Coordinating Center. The Ped-In Vivo-TP Coordinating Center will be responsible for integrating the activities of the individual Ped-In Vivo-TP Research Teams to create a functional collaboration for pediatric preclinical testing. Specifically, the Ped-In Vivo-TP Coordinating Center will be responsible for the following: 1) Administrative and logistical coordination; 2) Data management, statistical, and bioinformatics support; and 3) Scientific coordination and support.